Daily Alpha · YouTube
· Premarket Alpha · by Buzzberg Research
Who was talking 48 videos · 8 channels
Capital structure
1 video · 8mAI demand is no longer the only debate; financing terms and who bears residual-value risk now matter.
AI financing is abundant, but the deployment structure is still undefined
Bloomberg's financing discussion emphasized that the timing and structure of Nvidia's proposed infrastructure platforms were not yet known. The capital headline is large, but the underwriting terms still determine who ultimately bears utilization and residual-value risk.
Yield threshold
1 video · 5mThe 10-year Treasury near 4.8% is a concrete test for the equity upside case.
A 4.8% 10-year yield is the immediate equity stress line
Julian Emanuel said a 10-year Treasury yield above 4.8% would be difficult for equities, even while outlining a conditional path to a 9,000 S&P 500 in 2027. The bullish scenario therefore depends on long yields not overwhelming earnings and AI-financing optimism.
Political capacity
1 video · 1h 19mMeta's open-AI message was read as a campaign to improve the public license for more data centers.
Meta's open-AI message is also a bid for permission to build
Jason Calacanis interpreted Meta's techno-optimist manifesto as a public-relations trade: offer free agents, tutors, and tools while asking communities and regulators to accept more data centers. The claim is commentary, not a company disclosure, but it identifies political consent as a real capacity constraint.
Scandium's strategic value rests on qualification, not just scarcity
Sunrise Energy Metals' managing director said the company is actively working with defense users to qualify scandium for principal alloys. The interview is first-party company evidence, so execution and customer qualification still require independent confirmation.
Hims' branded GLP-1 shift expands access but raises the margin test
A Needham analyst described Hims as moving through a transition in both its core and weight-loss businesses and remained positive on branded GLP-1 demand. The case rests on patient acquisition opening additional care opportunities, while the margin outcome remains unproven.